HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026
Three abstracts accepted across HCB101 and HCB301,
including the gastric cancer Best Poster Presentation Award and Poster Discussion
TAIPEI, SHANGHAI, and SAN FRANCISCO — August 19, 2026 — HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), taking place September 2–4, 2026, in Seoul, Korea.
The presentations include two posters on HCB101 clinical development in gastric cancer (GC) and head and neck squamous cell carcinoma (HNSCC), as well as an oral presentation of first-in-human clinical data for HCB301, HanchorBio’s tri-specific SIRPα–PD-L1–TGFβ fusion protein.
The HCB101 gastric cancer abstract has also been selected for the KSMO 2026 Best Poster Presentation Award and a Poster Discussion presentation. According to KSMO, only outstanding abstracts were selected for the Poster Discussion sessions.
“We are pleased to have three clinical presentations selected for KSMO 2026 and FACO across two programs from our FBDB™ platform,” said Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio. “HCB101 and HCB301 represent our innovative approaches to overcoming immune resistance, from activating macrophage-mediated antitumor immunity to integrating and synergizing multiple immune pathways within a single therapeutic molecule. We look forward to sharing our progress with the oncology community in Seoul.”
Alvin Luk, Ph.D., M.B.A., C.C.R.A., President and Chief Medical Officer (Group) & CEO (USA) of HanchorBio, will deliver the HCB301 oral presentation.
HanchorBio Presentations at KSMO 2026 / FACO
- HCB101 — Gastric Cancer
Preliminary Antitumor Activity of HCB101 (SIRPα-Fc Fusion Protein)-Based Combination Therapy in Advanced Gastric Cancer- Presentation: Best Poster Presentation Award / Poster Discussion (In-Person Presentation)
- Date:September 3, 2026
- Poster Discussion Session:14:50–15:20 KST
- Presentation Format:4-minute presentation + 2-minute real-time Q&A
- Presentation Code/Location: PD01/Carnation Room (5 Floor)
- HCB101 — Head and Neck Squamous Cell Carcinoma
HCB101 in HNSCC: Early Clinical Evidence Supporting PD-1- and EGFR-Directed Combination Strategies- Presentation:Poster
- Date:September 3, 2026
- HCB301 — First-in-Human Phase 1 Study
Coordinated SIRPα-PD-L1-TGFβ Modulation with HCB301: Early Safety and Disease Control in a First-in-Human Phase 1 Study- Presentation:Oral Presentation (In-Person Presentation)
- Presenter:Alvin Luk, Ph.D., M.B.A., C.C.R.A.
- Date:September 4, 2026
- Session:14:40–15:40 KST
- Presentation Code/Location: OP02-1/Room D (Grand Ballroom)
- KSMO 2026 Best Poster Presentation Award Ceremony
- Date:September 4, 2026
- Time: 16:10–16:30 KST/Room C (Grand Ballroom)
“KSMO and FACO bring together an important community of oncologists and clinical investigators from across Asia and internationally,” said Dr. Luk. “The selection of HCB301 for oral presentation, together with two HCB101 presentations and the recognition of our gastric cancer work through the Best Poster Presentation Award, gives us an opportunity to present the growing clinical breadth of the FBDB™ platform. We look forward to discussing these programs and their potential to expand the therapeutic possibilities of cancer immunotherapy.”
The KSMO presentations will highlight HCB101’s clinical development in gastric cancer and HNSCC, including combination strategies with established anticancer therapies, as well as first-in-human clinical experience with HCB301 and its coordinated targeting of innate immune suppression, adaptive immune checkpoint signaling, and TGFβ-mediated immune exclusion.
Additional clinical data from the presentations will be shared following their presentation at KSMO 2026.
About HCB101
HCB101 is an investigational engineered SIRPα–IgG4 Fc fusion protein developed using HanchorBio’s proprietary FBDB™ platform. HCB101 blocks CD47–SIRPα signaling and is designed to enhance macrophage-mediated antitumor immunity. It is being evaluated as monotherapy (NCT05892718) and in combinations (NCT06771622) across solid and hematologic malignancies. HCB101 has received U.S. FDA Orphan Drug Designation for gastric cancer.
About HCB301
HCB301 is an investigational tri-specific SIRPα–PD-L1–TGFβ IgG4 fusion protein designed to coordinately modulate innate immunity, adaptive immunity, and TGFβ-mediated immune exclusion within a single therapeutic molecule. It is being evaluated in the ongoing first-in-human Phase 1 HCB301-101 study (NCT06487624).
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases. Its proprietary Fc-Based Designer Biologics (FBDB™) platform enables the engineering of multifunctional biologics designed to coordinately modulate complementary immune pathways.
HanchorBio’s pipeline includes clinical-stage programs HCB101 (a SIRPα-based innate immune checkpoint program) and HCB301 (a trispecific immunotherapy targeting SIRPα, PD-L1, and TGF-β biology), as well as next-generation programs including HCB303 and additional candidates across oncology and immune-mediated diseases. With operations in Taiwan, China, and the United States, HanchorBio integrates therapeutic engineering, translational science, clinical development, and global regulatory execution. For more information, please visit HanchorBio.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the development of HCB303, the timing and potential submission of an IND, initiation and design of future clinical studies, potential therapeutic characteristics and mechanisms of HCB303, development of HanchorBio’s pipeline, and the capabilities and potential of the FBDB™ platform. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described. Regulatory feedback does not constitute approval of an IND or assurance that clinical development will proceed as planned. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
漢康生技 HCB301 獲選 KSMO 2026 口頭報告 HCB101 胃癌研究榮獲最佳海報發表獎
HCB101 與 HCB301 共三篇摘要獲選發表，涵蓋胃癌最佳海報發表獎暨海報討論，以及 HCB301 首次人體臨床數據口頭報告
【台北／上海／舊金山，2026 年 8 月 19 日】－全球臨床階段生技公司漢康生技（TWSE：7827）致力於開發應用於腫瘤及免疫相關疾病的次世代免疫療法，今日宣布，公司臨床階段產品 HCB101 與 HCB301 共三篇研究摘要獲選於 KSMO 2026 發表。KSMO 2026 為韓國腫瘤內科學會第 19 屆年會暨 2026 國際大會，並與亞洲臨床腫瘤學聯盟（FACO）第 14 屆國際大會聯合舉行，將於 2026 年 9 月 2 日至 4 日於韓國首爾登場。
此次獲選內容包括兩篇 HCB101 臨床研究海報，分別聚焦胃癌（GC）與頭頸部鱗狀細胞癌（HNSCC）的臨床開發，以及 HCB301 首次人體臨床數據的口頭報告。HCB301 為漢康生技開發的三特異性 SIRPα–PD-L1–TGFβ 融合蛋白。
其中，HCB101 胃癌研究摘要進一步獲選為 KSMO 2026 最佳海報發表獎，並入選海報討論現場發表。依 KSMO 公布資訊，僅具突出表現的研究摘要會獲選進入海報討論場次。
漢康生技創辦人暨董事長劉世高博士表示：「我們很高興 HCB101 與 HCB301 兩項來自 FBDB™ 平台的臨床產品，共有三項研究獲選於 KSMO 2026 及 FACO 發表。HCB101 與 HCB301 分別代表漢康生技克服腫瘤免疫抗性的不同創新策略，從活化巨噬細胞介導的抗腫瘤免疫，到將多條免疫調控路徑整合並產生協同作用於單一治療分子之中。我們期待在首爾與腫瘤學界分享最新研究進展。」
漢康生技總裁暨醫療長（集團）及美國執行長陸英明博士將於大會中進行 HCB301 口頭報告。
漢康生技於 KSMO 2026／FACO 發表內容
HCB101－胃癌
以 HCB101（SIRPα-Fc 融合蛋白）為基礎的聯合治療於晚期胃癌中的初步抗腫瘤活性
- 發表形式：最佳海報發表獎／海報討論（現場發表）
- 日期：2026 年 9 月 3 日
- 海報討論場次：韓國時間 14:50–15:20
- 發表形式：4 分鐘簡報＋2 分鐘現場問答
- 發表編號／地點：PD01／Carnation Room（5 樓）
HCB101－頭頸部鱗狀細胞癌
HCB101 於頭頸部鱗狀細胞癌之臨床研究：支持 PD-1 與 EGFR 導向聯合治療策略的早期臨床證據
- 發表形式：海報
- 日期：2026 年 9 月 3 日
HCB301－首次人體 Phase 1 臨床研究
HCB301 協同調控 SIRPα、PD-L1 與 TGFβ：首次人體 Phase 1 臨床研究之早期安全性與疾病控制結果
- 發表形式：口頭報告（現場發表）
- 報告人：陸英明博士（Alvin Luk, Ph.D., M.B.A., C.C.R.A.）
- 日期：2026 年 9 月 4 日
- 場次時間：韓國時間 14:40–15:40
- 發表編號／地點：OP02-1／Room D（Grand Ballroom）
KSMO 2026 最佳海報發表獎頒獎典禮
- 日期：2026 年 9 月 4 日
- 時間：韓國時間 16:10–16:30
- 地點：Room C（Grand Ballroom）
陸英明博士表示：「KSMO 與 FACO 匯聚來自亞洲及全球的重要腫瘤科醫師與臨床研究者。HCB301 獲選口頭報告，加上 HCB101 兩項研究發表，以及胃癌研究獲頒最佳海報發表獎，讓我們有機會進一步展現 FBDB™ 平台持續擴展的臨床研究廣度。我們期待與各界交流這些產品的開發進展，以及其進一步拓展癌症免疫治療可能性的潛力。」
本次 KSMO 發表將聚焦 HCB101 在胃癌與頭頸部鱗狀細胞癌的臨床開發進展，包括與既有抗癌治療的聯合治療策略；同時亦將分享 HCB301 的首次人體臨床經驗，以及其同步調控先天免疫抑制、後天免疫檢查點訊號及 TGFβ 所介導免疫排斥機制的治療策略。
漢康生技將於相關研究於 KSMO 2026 正式發表後，進一步公布臨床數據。
關於 HCB101
HCB101 為漢康生技運用自主 FBDB™ 平台開發的試驗中新型 SIRPα–IgG4 Fc 融合蛋白。HCB101 透過阻斷 CD47–SIRPα 訊號，旨在增強巨噬細胞介導的抗腫瘤免疫作用。目前 HCB101 正於實體腫瘤及血液腫瘤中進行單藥治療（NCT05892718）及聯合治療（NCT06771622）臨床評估，並已取得美國 FDA 胃癌孤兒藥資格認定。
關於 HCB301
HCB301 為試驗中的三特異性 SIRPα–PD-L1–TGFβ IgG4 融合蛋白，旨在透過單一治療分子，同步調控先天免疫、後天免疫以及 TGFβ 所介導的免疫排斥。目前 HCB301 正於首次人體 Phase 1 臨床試驗 HCB301-101（NCT06487624）中進行評估。
關於漢康生技
漢康生技（HanchorBio，TWSE：7827）為全球臨床階段生技公司，專注於開發應用於腫瘤及免疫相關疾病的次世代免疫療法。公司自主開發的 Fc-Based Designer Biologics（FBDB™）平台，可用於設計多功能生物藥，藉由協同調控互補的免疫路徑，打造具差異化潛力的新型治療方案。
漢康生技產品管線包括臨床階段產品 HCB101，一項以 SIRPα 為基礎的先天免疫檢查點治療產品；以及 HCB301，一項同時作用於 SIRPα、PD-L1 與 TGF-β 生物路徑的三特異性免疫療法。此外，公司亦持續推進 HCB303 等下一代產品，以及其他涵蓋腫瘤與免疫相關疾病的候選藥物。漢康生技於台灣、中國及美國均設有營運據點，整合創新藥物工程、轉譯科學、臨床開發及全球法規執行能力。
前瞻性聲明
本新聞稿包含前瞻性聲明，包括有關 HCB303 的開發、IND 申請可能時程、未來臨床研究的啟動與設計、HCB303 潛在治療特性及作用機制、漢康生技產品管線的開發，以及 FBDB™ 平台之能力與潛力等相關陳述。上述聲明係基於目前的預期及假設，並涉及可能使實際結果與所述內容產生重大差異的風險與不確定性。監管機關的意見不代表 IND 已獲核准，亦不保證臨床開發將依計畫進行。除適用法律另有規定外，漢康生技不承擔更新前瞻性聲明之義務。